## Peter J Fuller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2849009/publications.pdf

Version: 2024-02-01

207 papers 7,993 citations

48 h-index

50566

78623 77 g-index

236 all docs

236 docs citations

times ranked

236

7868 citing authors

#	Article	IF	CITATIONS
1	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	0.8	19
2	Detecting primary aldosteronism in Australian primary care: a prospective study. Medical Journal of Australia, 2022, 216, 408-412.	0.8	29
3	Letter to the Editor. Risk factors for postoperative DI after transsphenoidal surgery: missing a pinch of SALT. Journal of Neurosurgery, 2022, , $1$ -2.	0.9	O
4	Cortisol resistance in the degu (Octodon degus). Steroids, 2022, 184, 109037.	0.8	0
5	Primary aldosteronism. BMJ, The, 2022, 377, e065250.	3.0	5
6	Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective. Journal of Human Hypertension, 2021, 35, 110-116.	1.0	18
7	Identifying new cellular mechanisms of mineralocorticoid receptor activation in the heart. Journal of Human Hypertension, 2021, 35, 124-130.	1.0	7
8	Comparison of ambulatory blood pressure between patients with primary aldosteronism and other forms of hypertension. Clinical Endocrinology, 2021, 94, 353-360.	1,2	6
9	Response to Letter to the Editor from Zhu and Rossi: "Development and Validation of Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1498-e1499.	1.8	O
10	Mutations of the Human Mineralocorticoid Receptor and Targeted Deletion in Model Organisms. , 2021, , 229-239.		0
11	Adrenal disease: An update. Australian Journal of General Practice, 2021, 50, 9-14.	0.3	1
12	Diabetes insipidus after endoscopic transsphenoidal surgery: multicenter experience and development of the SALT score. Pituitary, 2021, 24, 867-877.	1.6	23
13	Time of Day Regulates Renal Mineralocorticoid Receptor Transcriptional Control of Electrolyte Balance. Journal of the Endocrine Society, 2021, 5, A819-A820.	0.1	1
14	Relationship Between the Aldosterone-to-Renin Ratio and Blood Pressure in Young Adults: A Longitudinal Study. Hypertension, 2021, 78, 387-396.	1.3	6
15	Proanthocyanidins Maintain Cardiac Ionic Homeostasis in Aldosterone-Induced Hypertension and Heart Failure. International Journal of Molecular Sciences, 2021, 22, 9602.	1.8	3
16	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors. British Journal of Pharmacology, 2021, 178, S246-S263.	2.7	100
17	Hypertension Management in Stroke Prevention. Stroke, 2021, 52, e626-e634.	1.0	13
18	FOXL2 C134W : much ado about something!â€. Journal of Pathology, 2021, 256, 1.	2.1	2

#	Article	IF	Citations
19	A combination of captopril challenge test after saline infusion test improves diagnostic accuracy for primary aldosteronism. Clinical Endocrinology, 2020, 92, 131-137.	1.2	11
20	Simplifying the Diagnosis of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1296-1297.	1.8	0
21	A tumour suppressive relationship between mineralocorticoid and retinoic acid receptors activates a transcriptional program consistent with a reverse Warburg effect in breast cancer. Breast Cancer Research, 2020, 22, 122.	2.2	6
22	Primary Aldosteronism in Patients in China With Recently Detected Hypertension. Journal of the American College of Cardiology, 2020, 75, 1913-1922.	1.2	112
23	Primary aldosteronism is a public health issue: challenges and opportunities. Journal of Human Hypertension, 2020, 34, 478-486.	1.0	30
24	Impact of Victoria's first dedicated Endocrine Hypertension Service on the pattern of primary aldosteronism diagnoses. Internal Medicine Journal, 2020, 51, 1255-1261.	0.5	9
25	Age―and sexâ€specific reference ranges are needed for the aldosterone/renin ratio. Clinical Endocrinology, 2020, 93, 221-228.	1.2	15
26	Development and Validation of Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2449-e2456.	1.8	30
27	Novel mineralocorticoid receptor mechanisms regulate cardiac tissue inflammation in male mice. Journal of Endocrinology, 2020, 246, 123-134.	1.2	6
28	A Multicenter Study of Neutrophil-to-Lymphocyte Ratio in Primary Aldosteronism. Journal of the Endocrine Society, 2020, 4, bvaa153.	0.1	0
29	A multi-centre study of neutrophil-to-lymphocyte ratio in primary aldosteronism. Journal of the Endocrine Society, 2020, 4, bvaa153.	0.1	3
30	Molecular evolution of the switch for progesterone and spironolactone from mineralocorticoid receptor agonist to antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 18578-18583.	3.3	34
31	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors. British Journal of Pharmacology, 2019, 176, S229-S246.	2.7	127
32	Aldosterone; Action and Function., 2019,, 540-545.		0
33	Mutational Landscape of Ovarian Adult Granulosa Cell Tumors from Whole Exome and Targeted <i>TERT</i> Promoter Sequencing. Molecular Cancer Research, 2019, 17, 177-185.	1.5	36
34	Combined PPARÎ <sup>3</sup> Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors. Molecular Cancer Therapeutics, 2019, 18, 364-375.	1.9	15
35	Mechanisms of Mineralocorticoid Receptor Signaling. Vitamins and Hormones, 2019, 109, 37-68.	0.7	18
36	Targeting XIAP and PPAR $\hat{I}^3$ in Granulosa Cell Tumors Alters Metabolic Signaling. Journal of Proteome Research, 2019, 18, 1691-1702.	1.8	8

#	Article	IF	CITATIONS
37	Cardiomyocyte transcription is controlled by combined mineralocorticoid receptor and circadian clock signalling. Journal of Endocrinology, 2019, 241, 17-29.	1.2	12
38	SAT-056 Primary Aldosteronism Has a Distinctive Twenty-four Hour Blood Pressure Profile. Journal of the Endocrine Society, $2019, 3, .$	0.1	0
39	Is it time to screen all patients with hypertension for primary aldosteronism?. Medical Journal of Australia, 2018, 209, 57-59.	0.8	18
40	Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism. Clinical Endocrinology, 2018, 89, 308-313.	1.2	15
41	Current pattern of primary aldosteronism diagnosis: Delayed and complicated., 2018, 47, 712-718.		19
42	Optimizing bone health in cerebral palsy across the lifespan. Developmental Medicine and Child Neurology, 2017, 59, 232-233.	1.1	6
43	Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism butÂExacerbates Liver Damage in a Piglet Model of Short-BowelÂSyndrome. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 65-74.	2.3	14
44	Diagnosing endocrine hypertension: a practical approach. Nephrology, 2017, 22, 663-677.	0.7	14
45	Minimal-trauma ankle fractures predominate during pregnancy: a 17-year retrospective study. Archives of Osteoporosis, 2017, 12, 86.	1.0	9
46	Urolithiasis is prevalent and associated with reduced bone mineral density in βâ€thalassaemia major. Internal Medicine Journal, 2017, 47, 1064-1067.	0.5	10
47	Deoxycorticosterone/Salt-Mediated Cardiac Inflammation and Fibrosis Are Dependent on Functional CLOCK Signaling in Male Mice. Endocrinology, 2017, 158, 2906-2917.	1.4	18
48	30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Coregulators as mediators of mineralocorticoid receptor signalling diversity. Journal of Endocrinology, 2017, 234, T23-T34.	1.2	56
49	Genetics and genomics of ovarian sex cordâ€stromal tumors. Clinical Genetics, 2017, 91, 285-291.	1.0	43
50	Endocrine Affairs of the Heart. Endocrinology, 2016, 157, 2578-2582.	1.4	7
51	Proanthocyanidins block aldosterone-dependent up-regulation of cardiac gamma ENaC and Nedd4-2 inactivation via SGK1. Journal of Nutritional Biochemistry, 2016, 37, 13-19.	1.9	11
52	Adrenal Cushing's syndrome in pregnancy: Clinical and molecular characterisation of a case. Obstetric Medicine, 2016, 9, 43-45.	0.5	6
53	Bone Disease in Thalassemia: A Molecular and Clinical Overview. Endocrine Reviews, 2016, 37, 320-346.	8.9	51
54	Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages. Endocrinology, 2016, 157, 3213-3223.	1.4	47

#	Article	IF	CITATIONS
55	Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors. International Journal of Biochemistry and Cell Biology, 2016, 72, 51-54.	1.2	44
56	Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone, 2016, 85, 55-58.	1.4	25
57	Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks' gestation. American Journal of Obstetrics and Gynecology, 2016, 214, 521.e1.521.e8.	0.7	21
58	Aldosterone Secretion and Action., 2016, , 1756-1762.e3.		0
59	Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. Placenta, 2016, 48, 72-79.	0.7	9
60	Transcriptomic analysis of stage 1 versus advanced adult granulosa cell tumors. Oncotarget, 2016, 7, 14207-14219.	0.8	20
61	Tyrosine Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of Granulosa Cell Tumors of the Ovary. International Journal of Gynecological Cancer, 2015, 25, 1224-1231.	1.2	11
62	GEMIN4 functions as a coregulator of the mineralocorticoid receptor. Journal of Molecular Endocrinology, 2015, 54, 149-160.	1.1	22
63	Aldosterone-Mediated Renal Sodium Transport Requires Intact Mineralocorticoid Receptor DNA-Binding in the Mouse. Endocrinology, 2015, 156, 2958-2968.	1.4	9
64	Novel interactions of the mineralocorticoid receptor. Molecular and Cellular Endocrinology, 2015, 408, 33-37.	1.6	42
65	Somatic Mutations of FOXE1 in Papillary Thyroid Cancer. Thyroid, 2015, 25, 904-910.	2.4	12
66	Corticosteroid Receptors., 2015,, 17-39.		0
67	Beneficial Effects of Proanthocyanidins in the Cardiac Alterations Induced by Aldosterone in Rat Heart through Mineralocorticoid Receptor Blockade. PLoS ONE, 2014, 9, e111104.	1.1	12
68	PRMT2 and ROR $\hat{i}^3$ Expression Are Associated With Breast Cancer Survival Outcomes. Molecular Endocrinology, 2014, 28, 1166-1185.	3.7	45
69	Duelling Receptors: Estrogen Receptor Versus Mineralocorticoid Receptor in the Cardiovascular System. Endocrinology, 2014, 155, 4117-4119.	1.4	3
70	Breast cancer prognosis predicted by nuclear receptorâ€coregulator networks. Molecular Oncology, 2014, 8, 998-1013.	2.1	27
71	Nuclear Receptor Expression in Human Differentiated Thyroid Tumors. Thyroid, 2014, 24, 1000-1011.	2.4	16
72	Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease. Journal of Hepatology, 2014, 61, 1115-1125.	1.8	76

#	Article	lF	CITATIONS
73	Thalassemia Bone Disease: A 19-Year Longitudinal Analysis. Journal of Bone and Mineral Research, 2014, 29, 2468-2473.	3.1	50
74	Use of Phage Display to Identify Novel Mineralocorticoid Receptor-Interacting Proteins. Molecular Endocrinology, 2014, 28, 1571-1584.	3.7	39
75	Identification and characterization of a ligandâ€selective mineralocorticoid receptor coactivator. FASEB Journal, 2014, 28, 4200-4210.	0.2	29
76	Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Oncotarget, 2014, 5, 8651-8664.	0.8	22
77	Characterization of the Inhibitor of KappaB Kinase (IKK) Complex in Granulosa Cell Tumors of the Ovary and Granulosa Cell Tumor-Derived Cell Lines. Hormones and Cancer, 2013, 4, 277-292.	4.9	13
78	Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Research and Treatment, 2013, 142, 211-223.	1.1	45
79	An immunohistochemical and molecular analysis of problematic and unclassified ovarian sex cord–stromal tumors. Human Pathology, 2013, 44, 2774-2781.	1.1	29
80	Liver receptor homologue-1 expression in ovarian epithelial and granulosa cell tumours. Steroids, 2013, 78, 700-706.	0.8	16
81	Betaglycan Alters NFκB-TGFκ2 Cross Talk to Reduce Survival of Human Granulosa Tumor Cells. Molecular Endocrinology, 2013, 27, 466-479.	3.7	25
82	Disparate bedfellows in a lasting drug union?. Nature Reviews Endocrinology, 2013, 9, 135-136.	4.3	0
83	Research Resource: Nuclear Receptors as Transcriptome: Discriminant and Prognostic Value in Breast Cancer. Molecular Endocrinology, 2013, 27, 350-365.	3.7	98
84	HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors. Journal of Cancer, 2013, 4, 152-164.	1.2	31
85	Introduction. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 872-875.	0.9	1
86	The Helix 1-3 Loop in the Glucocorticoid Receptor LBD Is a Regulatory Element for FKBP Cochaperones. Molecular Endocrinology, 2013, 27, 1020-1035.	3.7	26
87	Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism. Clinical Biochemist Reviews, 2013, 34, 111-6.	3.3	6
88	Ovarian Actions of Estrogen Receptor-Î <sup>2</sup> : An Update. Seminars in Reproductive Medicine, 2012, 30, 32-38.	0.5	44
89	Molecular Pathogenesis of Granulosa Cell Tumors of the Ovary. Endocrine Reviews, 2012, 33, 109-144.	8.9	164
90	Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocrine-Related Cancer, 2012, 19, 509-526.	1.6	37

#	Article	IF	Citations
91	Mechanisms of ligand specificity of the mineralocorticoid receptor. Journal of Endocrinology, 2012, 213, 15-24.	1.2	84
92	Interactions of the mineralocorticoid receptor – Within and without. Molecular and Cellular Endocrinology, 2012, 350, 196-205.	1.6	46
93	Activin and inhibin, estrogens and NF $\hat{l}^2$ B, play roles in ovarian tumourigenesis is there crosstalk?. Molecular and Cellular Endocrinology, 2012, 359, 85-91.	1.6	9
94	What is in a name?. Molecular and Cellular Endocrinology, 2012, 350, 145.	1.6	2
95	A case of hypophosphatemic osteomalacia secondary to deferasirox therapy. Journal of Bone and Mineral Research, 2012, 27, 219-222.	3.1	21
96	Characterization of the zebrafish (Danio rerio) mineralocorticoid receptor. Molecular and Cellular Endocrinology, 2011, 332, 58-66.	1.6	75
97	Pseudohypoaldosteronism type 1: the index case revisited. Clinical Endocrinology, 2011, 74, 408-410.	1.2	4
98	Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors. Hormones and Cancer, 2011, 2, 157-169.	4.9	46
99	Identification of Ligand-Selective Peptide Antagonists of the Mineralocorticoid Receptor Using Phage Display. Molecular Endocrinology, 2011, 25, 32-43.	3.7	46
100	Mineralocorticoid and Epidermal Growth Factor Receptors. Hypertension, 2011, 57, 144-145.	1.3	7
101	The importance of $\mathrm{ER}\hat{\mathrm{I}}^2$ signalling in the ovary. Journal of Endocrinology, 2010, 205, 15-23.	1.2	95
102	Activation of Mineralocorticoid Receptors by Exogenous Glucocorticoids and the Development of Cardiovascular Inflammatory Responses in Adrenalectomized Rats. Endocrinology, 2010, 151, 2622-2628.	1.4	29
103	The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Modern Pathology, 2010, 23, 1477-1485.	2.9	195
104	Proteomic Analysis of the Intestinal Adaptation Response Reveals Altered Expression of Fatty Acid Binding Proteins Following Massive Small Bowel Resection. Journal of Proteome Research, 2010, 9, 1437-1449.	1.8	23
105	High-temperature requirement factor A3 (Htra3): A novel serine protease and its potential role in ovarian function and ovarian cancers. Molecular and Cellular Endocrinology, 2010, 327, 13-18.	1.6	26
106	Aromatase Is a Direct Target of FOXL2: C134W in Granulosa Cell Tumors via a Single Highly Conserved Binding Site in the Ovarian Specific Promoter. PLoS ONE, 2010, 5, e14389.	1.1	118
107	Aldosterone. , 2010, , 1831-1838.		0
108	Structural and Functional Characterization of the Interdomain Interaction in the Mineralocorticoid Receptor. Molecular Endocrinology, 2009, 23, 1360-1370.	3.7	62

#	Article	IF	CITATIONS
109	Loss of Betaglycan Contributes to the Malignant Properties of Human Granulosa Tumor Cells. Molecular Endocrinology, 2009, 23, 539-548.	3.7	51
110	Deletion of Mineralocorticoid Receptors From Macrophages Protects Against Deoxycorticosterone/Salt-Induced Cardiac Fibrosis and Increased Blood Pressure. Hypertension, 2009, 54, 537-543.	1.3	272
111	Proteasome Inhibition by Bortezomib Decreases Proliferation and Increases Apoptosis in Ovarian Granulosa Cell Tumors. Reproductive Sciences, 2009, 16, 397-407.	1.1	12
112	Purification and characterization of recombinant human mineralocorticoid receptor. Molecular and Cellular Endocrinology, 2009, 302, 81-85.	1.6	18
113	Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart. Clinical Science, 2009, 116, 731-739.	1.8	41
114	Expression Status and Mutational Analysis of the PTEN and P13K Subunit Genes in Ovarian Granulosa Cell Tumors. International Journal of Gynecological Cancer, 2009, 19, 339-342.	1.2	23
115	Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecologic Oncology, 2008, 108, 182-190.	0.6	30
116	Structure–function relationships in the mineralocorticoid receptor. Journal of Molecular Endocrinology, 2008, 41, 405-413.	1.1	72
117	Colostrum Supplementation Restores Insulinâ€like Growth Factor â€1 Levels and Alters Muscle Morphology Following Massive Small Bowel Resection. Journal of Parenteral and Enteral Nutrition, 2008, 32, 266-275.	1.3	45
118	Stem Cells in Endocrine Research: More than Just Dolly. Endocrinology, 2008, 149, 4301-4302.	1.4	0
119	Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis, 2008, 29, 2062-2072.	1.3	78
120	GLPâ€2 Administration Results in Increased Proliferation but Paradoxically an Adverse Outcome in a Juvenile Piglet Model of Short Bowel Syndrome. Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 20-28.	0.9	38
121	Management of granulosa cell tumour of the ovary. Current Opinion in Oncology, 2008, 20, 560-564.	1.1	41
122	A Direct Effect of Aldosterone on Endothelin-1 Gene Expressionin Vivo. Endocrinology, 2007, 148, 1511-1517.	1.4	43
123	Does Glucocorticoid Receptor Blockade Exacerbate Tissue Damage after Mineralocorticoid/Salt Administration?. Endocrinology, 2007, 148, 4829-4835.	1.4	17
124	A Critical Region in the Mineralocorticoid Receptor for Aldosterone Binding and Activation by Cortisol: Evidence for a Common Mechanism Governing Ligand Binding Specificity in Steroid Hormone Receptors. Molecular Endocrinology, 2007, 21, 817-828.	3.7	37
125	Isolated ACTH deficiency presenting as severe hypercalcaemia. Clinical Endocrinology, 2007, 66, 070215015809003-???.	1.2	8
126	Gene expression in the adapting small bowel after massive small bowel resection. Journal of Gastroenterology, 2006, 41, 1041-1052.	2.3	7

#	Article	IF	Citations
127	Mineralocorticoid Receptor Blockade But Not Steroid Withdrawal Reverses Renal Fibrosis in Deoxycorticosterone/Salt Rats. Endocrinology, 2006, 147, 3623-3629.	1.4	42
128	The aldosterone receptor – new insights?. Expert Opinion on Investigational Drugs, 2006, 15, 201-203.	1.9	2
129	Mammalian K-ras2 Is a Corticosteroid-Induced Gene in Vivo. Endocrinology, 2006, 147, 2809-2816.	1.4	17
130	The Role of the Glucocorticoid Receptor in Mineralocorticoid/Salt-Mediated Cardiac Fibrosis. Endocrinology, 2006, 147, 5901-5906.	1.4	33
131	International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors. Pharmacological Reviews, 2006, 58, 782-797.	7.1	350
132	Seladin-1/DHCR24 expression in normal ovary, ovarian epithelial and granulosa tumours. Clinical Endocrinology, 2005, 63, 111-115.	1.2	19
133	Expression of Steroid Receptor Coactivators in Cultured Cells From Paired Myometrial and Fibroid Tissues. Journal of the Society for Gynecologic Investigation, 2005, 12, 445-451.	1.9	6
134	Mechanisms of Mineralocorticoid Action. Hypertension, 2005, 46, 1227-1235.	1.3	273
135	Mechanisms of Mineralocorticoid Action. Hypertension, 2005, 46, 1227-1235.	1.3	4
136	Transrepression of Estrogen Receptor β Signaling by Nuclear Factor-κB in Ovarian Granulosa Cells. Molecular Endocrinology, 2004, 18, 1919-1928.	3.7	97
137	Endocrine Disorders of Sodium Regulation. Hormone Research in Paediatrics, 2004, 61, 68-83.	0.8	14
138	Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor*. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 704-709.	0.9	42
139	Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors. Gynecologic Oncology, 2004, 95, 603-609.	0.6	19
140	Plasma GLP-2 Levels and Intestinal Markers in the Juvenile Pig During Intestinal Adaptation: Effects of Different Diet Regimens. Digestive Diseases and Sciences, 2004, 49, 1688-1695.	1.1	33
141	Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends in Endocrinology and Metabolism, 2004, 15, 122-128.	3.1	68
142	Aldosterone and DNA: the 50th anniversary. Trends in Endocrinology and Metabolism, 2004, 15, 143-146.	3.1	4
143	Cortisol resistance in the New World revisited. Trends in Endocrinology and Metabolism, 2004, 15, 296-299.	3.1	40
144	Mineralocorticoid receptor binding, structure and function. Molecular and Cellular Endocrinology, 2004, 217, 203-212.	1.6	52

#	Article	IF	CITATIONS
145	Colostrum Protein Concentrate Enhances Intestinal Adaptation After Massive Small Bowel Resection in Juvenile Pigs. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 487-492.	0.9	41
146	Interdomain interactions in the mineralocorticoid receptor. Molecular and Cellular Endocrinology, 2003, 200, 45-55.	1.6	96
147	Dissecting mineralocorticoid receptor structure and function. Journal of Steroid Biochemistry and Molecular Biology, 2003, 85, 389-396.	1.2	29
148	17î²-Hydroxysteroid Dehydrogenase Type XI Localizes to Human Steroidogenic Cells. Endocrinology, 2003, 144, 2084-2091.	1.4	56
149	Sertoli-Leydig Cell Tumor of the Ovary, a Rare Cause of Precocious Puberty in a 12-Month-Old Infant. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 49-56.	1.8	24
150	Inhibin-Activin Receptor Subunit Gene Expression in Ovarian Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1395-1401.	1.8	36
151	Estrogen receptor-alpha and -beta expression in microvascular endothelial cells and smooth muscle cells of myometrium and leiomyoma. Molecular Human Reproduction, 2002, 8, 770-775.	1.3	34
152	$17\hat{l}^2$ -Estradiol Up-Regulates Vascular Endothelial Growth Factor Receptor-2 Expression in Human Myometrial Microvascular Endothelial Cells: Role of Estrogen Receptor- $\hat{l}\pm$ and $-\hat{l}^2$ . Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4341-4349.	1.8	51
153	Molecular pathogenesis of granulosa cell tumours. Molecular and Cellular Endocrinology, 2002, 191, 89-96.	1.6	39
154	Pseudohypoaldosteronism: kidney, lungs and colon*. Clinical Endocrinology, 2002, 56, 571-572.	1.2	6
155	Influence of diet complexity on intestinal adaptation following massive small bowel resection in a preclinical model. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 1170-1179.	1.4	53
156	Specificity in mineralocorticoid versus glucocorticoid action. Kidney International, 2000, 57, 1256-1264.	2.6	62
157	Acute differential regulation by corticosteroids of epithelial sodium channel subunit and Nedd4 mRNA levels in the distal colon. Pflugers Archiv European Journal of Physiology, 2000, 441, 94-101.	1.3	25
158	Estrogen Receptor Isoform Gene Expression in Ovarian Stromal and Epithelial Tumors*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1200-1205.	1.8	81
159	Rapid upregulation of serum and glucocorticoid-regulated kinase (sgk) gene expression by corticosteroids in vivo. Molecular and Cellular Endocrinology, 2000, 166, 129-136.	1.6	96
160	Humoral Factors in Intestinal Adaptation. Trends in Endocrinology and Metabolism, 2000, 11, 401-405.	3.1	31
161	Mineralocorticoid action. Steroids, 2000, 65, 61-73.	0.8	105
162	Acute Regulation by Corticosteroids of Channel-Inducing Factor Gene Messenger Ribonucleic Acid in the Distal Colon*. Endocrinology, 1999, 140, 1213-1218.	1.4	34

#	Article	IF	Citations
163	Comment on Analysis of Mutations in Genes of the Follicle-Stimulating Hormone Receptor in Ovarian Granulosa Cell Tumors. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3852-3852.	1.8	10
164	Structural Determinants of Aldosterone Binding Selectivity in the Mineralocorticoid Receptor. Journal of Biological Chemistry, 1999, 274, 36305-36311.	1.6	63
165	Cushing's syndrome secondary to ectopic ACTH secretion from metastatic breast carcinoma. Clinical Endocrinology, 1999, 50, 675-678.	1.2	14
166	TRANSCRIPTIONAL CONTROL BY CORTICOSTEROIDS OF CHIF GENE EXPRESSION IN THE RAT DISTAL COLON. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 489-491.	0.9	11
167	Inhibin Subunit Gene Expression in Ovarian Cancer. Gynecologic Oncology, 1999, 73, 273-279.	0.6	52
168	mRNA Levels of Dipeptidyl Peptidase IV Decrease during Intestinal Adaptation. Journal of Surgical Research, 1999, 87, 130-133.	0.8	20
169	Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression1This work was supported by a grant from the Crohn's and Colitis Foundation of America.1. Molecular and Cellular Endocrinology, 1998, 141, 179-186.	1.6	146
170	Intracellular Signaling Pathways Confer Specificity of Transactivation by Mineralocorticoid and Glucocorticoid Receptors*. Endocrinology, 1998, 139, 1653-1661.	1.4	37
171	Structural Determinants of Cortisol Resistance in the Guinea Pig Glucocorticoid Receptor <sup>1</sup> . Endocrinology, 1998, 139, 2479-2485.	1.4	47
172	No Evidence of a Role for Mutations or Polymorphisms of the Follicle-Stimulating Hormone Receptor in Ovarian Granulosa Cell Tumors < sup > 1 < /sup > . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 274-279.	1.8	62
173	Cautionary note on the use of end-labelling DNA fragments for detection of apoptosis. Pathology, 1998, 30, 267-271.	0.3	32
174	Determinants of Specificity of Transactivation by the Mineralocorticoid or Glucocorticoid Receptor*. Endocrinology, 1997, 138, 2537-2543.	1.4	65
175	Aldosteroneʽs effects and mechanism of action. Current Opinion in Endocrinology, Diabetes and Obesity, 1997, 4, 218-224.	0.6	22
176	Identification of a splice variant of the rat estrogen receptor $\hat{l}^2$ gene. Molecular and Cellular Endocrinology, 1997, 132, 195-199.	1.6	151
177	Insulin gene expression in adult-onset nesidioblastosis. Clinical Endocrinology, 1997, 47, 245-250.	1.2	8
178	The inhibin/activin family and ovarian cancer. Trends in Endocrinology and Metabolism, 1996, 7, 197-202.	3.1	13
179	Towards Understanding the Process of Intestinal Adaptation. Digestive Diseases, 1996, 14, 59-72.	0.8	33
180	Epithelial sodium channels and hypertension. Journal of Hypertension, 1996, 14, 1383-1386.	0.3	6

#	Article	IF	CITATIONS
181	Anomalies in the Endocrine Axes of the Guinea Pig: Relevance to Human Physiology and Disease*. Endocrine Reviews, 1996, 17, 30-44.	8.9	40
182	POU-domain gene expression in the gastrointestinal tract. Journal of Cellular Biochemistry, 1995, 58, 260-267.	1.2	9
183	Human Mineralocorticoid Receptor Genomic Structure and Identification of Expressed Isoforms. Journal of Biological Chemistry, 1995, 270, 21016-21020.	1.6	131
184	Cortisol resistance and the guinea pig glucocorticoid receptor. Steroids, 1995, 60, 87-92.	0.8	41
185	Aldosterone and its mechanism of action: more questions than answers. Australian and New Zealand Journal of Medicine, 1995, 25, 800-807.	0.5	5
186	7 Humoral regulation of intestinal adaptation. Bailliere's Clinical Endocrinology and Metabolism, 1994, 8, 165-183.	1.0	30
187	6 Mineralocorticoid resistance. Bailliere's Clinical Endocrinology and Metabolism, 1994, 8, 333-355.	1.0	43
188	Tarsal Navicular Stress Fracture in Athletes. Sports Medicine, 1994, 17, 65-76.	3.1	137
189	lleal proglucagon gene expression in the rat: Characterization in intestinal adaptation using in situ hybridization. Gastroenterology, 1993, 104, 459-466.	0.6	64
190	Outcome of conservative and surgical management of navicular stress fracture in athletes. American Journal of Sports Medicine, 1992, 20, 657-666.	1.9	173
191	Divergent ileal IGF-I and IGFBP-3 gene expression after small bowel resection: a novel mechanism to amplify IGF action?. Molecular and Cellular Endocrinology, 1992, 83, R17-R20.	1.6	40
192	Characterization of Renal Na-K-ATPase Gene Expression by in situ Hybridization. Kidney and Blood Pressure Research, 1992, 15, 10-15.	0.9	2
193	The steroid receptor superfamily: mechanisms of diversity. FASEB Journal, 1991, 5, 3092-3099.	0.2	194
194	lleal glucagon gene expression: Ontogeny and response to massive small bowel resection. Gastroenterology, 1990, 99, 724-729.	0.6	79
195	Mineralocorticoid receptor gene expression in the gastrointestinal tract: Distribution and ontogeny. The Journal of Steroid Biochemistry, 1990, 36, 263-267.	1.3	48
196	Colonic Sodium-Potassium Adenosine Triphosphate Subunit Gene Expression: Ontogeny and Regulation by Adrenocortical Steroids*. Endocrinology, 1990, 127, 32-38.	1.4	75
197	Steroid receptors as oncogenes?. Molecular and Cellular Endocrinology, 1988, 59, 161-164.	1.6	4
198	Kallikrein gene expression in estrogen-induced pituitary tumors. Molecular and Cellular Endocrinology, 1988, 60, 225-232.	1.6	28

## PETER J FULLER

#	Article	IF	CITATIONS
199	THE CLONING OF THE STEROID HORMONE RECEPTORS: BASIC AND CLINICAL IMPLICATIONS. Australian and New Zealand Journal of Medicine, 1988, 18, 890-896.	0.5	1
200	Estrogen Regulation of Kallikrein Gene Expression in the Rat Anterior Pituitary*. Endocrinology, 1986, 119, 268-273.	1.4	61
201	Expression of the Renal Kallikrein Gene in Mineralocorticoid-Treated and Genetically Hypertensive Rats. Journal of Hypertension, 1986, 4, 427-433.	0.3	17
202	The cellular physiology of glandular kallikrein. Kidney International, 1986, 29, 953-964.	2.6	49
203	A common 43 K protein induced by glucocorticoids in a variety of cells and tissues. Molecular and Cellular Endocrinology, 1984, 37, 197-204.	1.6	5
204	Mineralocorticoid and glucocorticoid receptors in human kidney. Kidney International, 1976, 10, 154-157.	2.6	38
205	Genetics and Mutational Landscape of Ovarian Sex Cord-Stromal Tumors., 0, , .		1
206	Intracellular Signaling Pathways Confer Specificity of Transactivation by Mineralocorticoid and Glucocorticoid Receptors., 0,.		15
207	Structural Determinants of Cortisol Resistance in the Guinea Pig Glucocorticoid Receptor. , 0, .		13